248 related articles for article (PubMed ID: 15190239)
1. Acetylcholinesterase and its inhibition in Alzheimer disease.
Lane RM; Kivipelto M; Greig NH
Clin Neuropharmacol; 2004; 27(3):141-9. PubMed ID: 15190239
[TBL] [Abstract][Full Text] [Related]
2. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
3. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.
Rees TM; Brimijoin S
Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110
[TBL] [Abstract][Full Text] [Related]
4. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD.
del Monte-Millán M; García-Palomero E; Valenzuela R; Usán P; de Austria C; Muñoz-Ruiz P; Rubio L; Dorronsoro I; Martínez A; Medina M
J Mol Neurosci; 2006; 30(1-2):85-8. PubMed ID: 17192640
[TBL] [Abstract][Full Text] [Related]
5. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
[TBL] [Abstract][Full Text] [Related]
6. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
Moss DE; Perez RG
Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
[TBL] [Abstract][Full Text] [Related]
7. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B; Singh N
Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.
Galdeano C; Viayna E; Arroyo P; Bidon-Chanal A; Blas JR; Muñoz-Torrero D; Luque FJ
Curr Pharm Des; 2010; 16(25):2818-36. PubMed ID: 20698824
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
10. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Castro A; Martinez A
Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
[TBL] [Abstract][Full Text] [Related]
11. Heterocyclic inhibitors of AChE acylation and peripheral sites.
Bolognesi ML; Andrisano V; Bartolini M; Cavalli A; Minarini A; Recanatini M; Rosini M; Tumiatti V; Melchiorre C
Farmaco; 2005; 60(6-7):465-73. PubMed ID: 15878569
[TBL] [Abstract][Full Text] [Related]
12. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
13. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
14. Acetylcholinesterase inhibitors: novel activities of old molecules.
Racchi M; Mazzucchelli M; Porrello E; Lanni C; Govoni S
Pharmacol Res; 2004 Oct; 50(4):441-51. PubMed ID: 15304241
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.
Muñoz-Torrero D
Curr Med Chem; 2008; 15(24):2433-55. PubMed ID: 18855672
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease.
Toublet FX; Lecoutey C; Lalut J; Hatat B; Davis A; Since M; Corvaisier S; Freret T; Sopkova de Oliveira Santos J; Claeysen S; Boulouard M; Dallemagne P; Rochais C
Molecules; 2019 Jul; 24(15):. PubMed ID: 31370232
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease.
de Almeida JR; Figueiro M; Almeida WP; de Paula da Silva CHT
Future Med Chem; 2018 May; 10(9):1037-1053. PubMed ID: 29676170
[TBL] [Abstract][Full Text] [Related]
18. Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease.
Wang H; Zhang H
ACS Chem Neurosci; 2019 Feb; 10(2):852-862. PubMed ID: 30521323
[TBL] [Abstract][Full Text] [Related]
19. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.
Zheng H; Fridkin M; Youdim MB
Curr Drug Targets; 2012 Jul; 13(8):1089-106. PubMed ID: 22676912
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
